Novavax Shifts From COVID Sales to R&D Focus While Updating 2025 Forecast

Novavax, Inc. (NASDAQ:NVAX) ranks among the most oversold biotech stocks to put in. Novavax, Inc. (NASDAQ:NVAX) announced its third-quarter 2025 fiscal results connected November 6, emphasizing the company’s continuous strategical displacement from a nonstop COVID-19 commercialized cognition to an R&D-focused company, particularly successful concern with Sanofi.

For the 3rd quarter, Novavax, Inc. (NASDAQ:NVAX) reported full gross of $70 million, an 18% driblet from $85 cardinal during the aforesaid play the erstwhile year. Meanwhile, licensing, royalties, and different gross roseate from $43 cardinal to $57 cardinal arsenic merchandise income fell sharply from $41 cardinal to $13 cardinal year-over-year.

Additionally, the institution expressed assurance successful its concern strategy and royalty channels by raising its full-year 2025 adjusted gross projection to $1,040–$1,060 million. Novavax, Inc. (NASDAQ:NVAX) further projects $610 cardinal successful Nuvaxovid merchandise sales, and $35–45 cardinal successful adjusted proviso sales.

More recently, connected November 10, B. Riley Securities expert Mayank Mamtani reiterated his Buy standing for Novavax, Inc. (NASDAQ:NVAX), portion reducing its terms people from $18 to $16.

Novavax, Inc. (NASDAQ:NVAX) is simply a biotechnology institution that develops and commercializes innovative vaccines to forestall superior infectious diseases. Its products are protein-based, utilizing recombinant nanoparticle exertion and its proprietary Matrix-M adjuvant to heighten the immune response.

While we admit the imaginable of NVAX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.